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Nocturnin (NOC) is a circadian-regulated protein related to the yeast
family of transcription factors involved in the cellular response to
nutrient status. In mammals, NOC functions as a deadenylase but
lacks a transcriptional activation domain. It is highly expressed in
bone-marrow stromal cells (BMSCs), hepatocytes, and adipocytes. In
BMSCs exposed to the PPAR-γ (peroxisome proliferator-activated
receptor-γ) agonist rosiglitazone, Noc expression was enhanced
30-fold. Previously, we reported that Noc−/− mice had low body
temperature, were protected from diet-induced obesity, and most
importantly exhibited absence of Pparg circadian rhythmicity on
a high-fat diet. Consistent with its role in influencing BMSCs alloca-
tion, Noc−/− mice have reduced bone marrow adiposity and high
bone mass. In that same vein, NOC overexpression enhances adipo-
genesis in 3T3-L1 cells but negatively regulates osteogenesis in
MC3T3-E1 cells. NOC and a mutated form, which lacks deadenylase
activity, bind to PPAR-γ and markedly enhance PPAR-γ transcrip-
tional activity. Both WT and mutant NOC facilitate nuclear translo-
cation of PPAR-γ. Importantly, NOC-mediated nuclear translocation
of PPAR-γ is blocked by a short peptide fragment of NOC that inhib-
its its physical interaction with PPAR-γ. The inhibitory effect of this
NOC-peptide was partially reversed by rosiglitazone, suggesting
that effect of NOC on PPAR-γ nuclear translocation may be indepen-
dent of ligand-mediated PPAR-γ activation. In sum, Noc plays a
unique role in the regulation of mesenchymal stem-cell lineage al-
location by modulating PPAR-γ activity through nuclear transloca-
tion. These data illustrate a unique mechanism whereby a nutrient-
responsive gene influences BMSCs differentiation, adipogenesis,
and ultimately body composition.
Several lines of evidence demonstrate a relationship betweencircadian networks and adipogenesis. For example, alter-
ations in time-keeping among individuals on psychotropic drugs,
nighttime shift workers, or those with hormonal imbalances are
often associated with fat redistribution (1–3). The nuclear re-
ceptor and transcription factor PPAR (peroxisome proliferator-
activated receptor)-γ2 and PGC-1α (PPAR-γ coactivator 1-α)
both exhibit cell-autonomous circadian patterns of gene ex-
pression (4). PPAR-γ2 is also critical in mesenchymal cell spec-
ification (5), a process under the influence of circadian networks.
Activation of PPAR-γ2 with aging or by the PPAR-γ agonist
rosiglitazone is negatively correlated with osteogenesis and
positively with bone marrow adipogenesis, although Pparg hap-
loinsufficiency in mice results in high bone mass, leanness, and
little marrow fat (5, 6).
Mammalian time-keeping is regulated by hypothalamic and
peripheral clock genes (7–11). Nocturnin (Noc; Ccrn4l) is one of
several cell-autonomous circadian genes (12) whose expression is
high in liver, hypothalamus, and adipocytes, and whose pro-
duction peaks in early night (13). Noc encodes a deadenylase
that removes poly-A tails from the 3′ ends of mRNAs (14, 15).
Previously, we reported that Noc gene expression was up-
regulated nearly 30-fold in bone-marrow stromal cells (BMSCs)
transfected with Pparg2 and exposed to rosiglitazone (16). Simi-
larly, in a congenic mouse with low bone mass and increased Pparg
activity, Noc transcripts were markedly enhanced in liver, fat, and
bone marrow (17). In hepatic and skeletal tissues from aging
rodents, there is increased Noc expression coincident with greater
PPAR-γ2 activity, low bone mass, and greater bone-marrow adi-
posity (18). In addition, we have also shown that Noc−/− mice are
protected from diet-induced obesity and exhibited absence of
circadian Pparg expression, even on a high-fat diet (19). These
data led us to hypothesize there is an important interaction be-
tween NOC and PPAR-γ that facilitates adipogenesis. Here, we
present the molecular mechanism underlying this interaction in
which NOC stimulates PPAR-γ function by facilitating its nuclear
localization. These observations suggest that Noc modulates
BMSCs fate by shifting stem cells into the adipogenic lineage and
away from osteoblast differentiation. More importantly, these
lines of evidence reinforce the importance of circadian networks in
the regulation of body composition.
Results
Noc Stimulates Adipogenesis and Suppresses Osteoblastogenesis.
First, to understand the role of Noc during mesenchymal stro-
mal cell differentiation, the critical first step in osteoblast and
adipocyte differentiation, we examined the temporal profile of
Noc expression. We found Noc was up-regulated during adipo-
genesis in both 3T3-L1 andOP9 cells (Fig. 1A and B and Fig S1).
Surprisingly, Noc expression was induced coincident with
PPAR-γ1 in early adipogenesis and before PPAR-γ2 (Fig. 1B).
Overexpression of Noc in 3T3-L1 cells markedly stimulated
adipogenesis and was accompanied by a significant increase in
aP2 (fatty acid-binding protein 4) and Pparg2 expression (Fig. 1
C and D and Fig S2). Consistently, knockdown of Noc in 3T3-L1
cells suppressed adipogenesis and was associated with reduced
expression of adipogenic markers including Pparg2, aP2, and Lpl
(lipoprotein lipase) (Fig. 1 E and F and Fig S2). In contrast, Noc
expression was down-regulated during osteoblastogenesis of
primary calvarial osteoblasts (COBs) (Fig. 1 G and H), and
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COBs derived from Noc−/− mice had lower Pparg and higher
Runx2 expression compared with controls (Fig S3A). Over-
expression of Noc in MC3T3-E1 cells suppressed osteoblasto-
genesis with reduced expression of alkaline phosphatase (ALP)
and Osteocalcin (OC) (Fig. 1 I and J and Fig S2), whereas
knockdown of Noc in MC3T3-E1 cells stimulated osteoblasto-
genesis with increased expression ofALP andOC (Fig. 1 K andL
and Fig S2). Consistent with this, Noc −/− COBs, when exposed
to osteogenic media, also showed enhanced osteogenesis com-
pared with control cells (Fig. 1M andN). The findings that NOC
enhances Pparg2 expression and decreases Runx2 expression led
us to hypothesize that NOC affects the transcription of these
genes. To test this tenet, we performed reporter assays using
luciferase vectors fused with either the Runx2 promoter (0.6 kb)
or the Pparg2 promoter (0.9 kb). To investigate whether the
deadenylase activity of NOC is involved in this regulation, we
also used a magnesium-binding motif mutant of NOC (E193A-
Noc), which lacked deadenylase activity. However, neither WT
nor mutant NOC affected the luciferase activity of these con-
structs (Fig S3B). The increase in Runx2 expression in Noc−/−
COBs was not accompanied by a craniofacial phenotype, which
was assessed at postnatal day 7 by inspection with microCT
(Fig S3C). Notwithstanding, because the promoter size inserted
in these luciferase vectors is small, we cannot exclude the pos-
sibility that the regulatory region may exist outside of tested
promoter fragments. In sum, Noc modulates BMSCs’ fate by
shifting cells into the adipogenic pathway and away from the
osteoblast lineage.
NOC Is Physically and Functionally Associated with PPAR-γ Indepen-
dent of Its Deadenylase Activity. Based on the temporal profile of
Noc expression in adipocytes, we next sought to determine
whether Noc influenced adipogenesis by regulating PPAR-γ. As
described previously, NOC had no effect on the activity of the
luciferase vector containing Pparg2 promoter, but interestingly,
we found that NOC coimmunoprecipitated with both PPAR-γ1
and PPAR-γ2, demonstrating a physical interaction between
these proteins (Fig. 2A and Fig S4A). Based on the exclusive
expression and the critical role of Pparg2 in adipocytes, we an-
alyzed the interaction between Pparg2 and Noc in this study. In
a reporter assay using a luciferase vector containing a Pparg re-
sponse element, WT Noc did not affect the basal Pparg2 tran-
scriptional activity, but Pparg2 transcriptional activation by
rosiglitazone was significantly increased in the presence of WT
Noc in murine marrow-derived UAMS-33 cells stably expressing
Pparg2 expression vector (U-33/γ2 cells) (Fig. 2B). Consistently,
Fig. 1. NOC favors adipogenesis over osteoblastogenesis. (A and B) 3T3-L1
cells were treated with control media (cont or C) or adipogenic mixture
(Adipo or A) for 9 d. Expression of aP2 and Noc was analyzed by real-time
PCR (n = 3) (A), and protein levels of PPAR-γ and Noc were determined by
Western blot analysis at indicated time points (B). (C and D) GFP or Noc
overexpressing 3T3-L1 cells were treated with adipogenic mixture. At day 7,
Oil-red O staining (C) and real-time PCR for aP2 and Pparg2 (D) were per-
formed (n = 3). (E) 3T3-L1 cells stably expressing either control or Noc-shRNA
were treated with adipogenic media, and Oil-red O staining was performed
at day 7. (F) Noc expression was suppressed using siRNA in 3T3-L1 cells. At
indicated time points after adipogenic induction, expression of marker
genes for adipogenesis was analyzed by real-time PCR (n = 3). Expression of
Noc, Pparg2, aP2, and C/EBPα was normalized to 36B4 and expression of LPL
and RXRα was normalized to β2-microglobulin. (G and H) Primary COBs from
Noc+/+ and Noc−/− mice were treated with control (con) or osteogenic (OB)
media for 11 d. Noc expression during osteoblastogenesis was analyzed in
Noc+/+ cells using real-time PCR (n = 4) (G) and Western blot analysis (H). (I
and J) GFP or Noc overexpressing MC3T3-E1 cells were treated with osteo-
genic media. At days 7 and 28, alkaline phosphatase (ALP) and Von Kossa
staining (I), and real-time PCR for ALP, and OC were performed (n = 3) (J). (K
and L) MC3T3-E1 cells stably expressing either control or Noc-shRNA were
treated with osteogenic media. ALP and Von Kossa staining (K) were per-
formed at day 7 and 28, and expression of ALP and OC were examined by
real-time PCR at day 28 (n = 3) (L). (M and N) Primary COBs from Noc+/+ and
Noc−/− mice were treated with osteogenic media, and ALP and Von Kossa
staining (M), and real-time PCR for Runx2, ALP, and OC were performed at
day 11 (n = 5) (N). Figures shown are the representative of at least three
independent experiments. Values are expressed as the mean ± SEM. †, P <
0.001; *, P < 0.01; **, P < 0.05.
Fig. 2. NOC is physically and functionally associated with PPAR-γ2 in
a deadenylase-independent manner. (A) HEK293 cells were tranfected with
WT-Noc-Flag or E193A-Noc-Flag, or a Pparg2-expression vector. Immuno-
precipitation with Flag was followed by Western blot analysis for PPAR-γ. (B)
Reporter assay using Pparg response element (PPRE) containing luciferase
vector in the presence or absence of 1 μM rosiglitazone (n = 3) was per-
formed using murine marrow-derived UAMS-33 cells stably expressing
Pparg2-expression vector (U-33/γ2 cells). (C) C3H10T1/2 cells overexpressing
Noc or GFP were transfected with Pparg2-expression vector, and treated
with 10 μg/mL cycloheximide. Whole-cell lysate was collected at indicated
time points, and expression of PPAR-γ, Noc, and β-actin was examined by
Western blot analysis. (D) HEK293 cells were transfected with WT-Noc-Flag
or E193A-Noc-Flag expression vector, and cell fractionation was performed.
Noc expression was analyzed by Western blot analysis with anti-Flag anti-
body. β-actin and Histone-H3 were examined as a positive control for cytosol
and nuclear protein, respectively. (E) HEK293 cells were cotransfected with
WT-Noc-Flag and a Pparg2-expression vector and treated with 5 μM of
rosiglitazone. Noc and Pparg expression were visualized by immunofluo-
rescence using anti-Flag antibody and anti-PPAR-γ antibody. Figures shown
are the representative of at least three independent experiments. Values are
expressed as the mean ± SEM. *, P < 0.05.








Pparg2 transcriptional activation by rosiglitazone was impaired in
Noc-deficient mouse embryonic fibroblasts (MEFs) compared
with WT MEFs, although basal transcriptional activity was com-
parable between WT and Noc−/− MEFs (Fig. 3A). To examine
whether physical binding of NOC to PPAR-γ2 caused any alter-
ation in the stability of PPAR-γ2, C3H10T1/2 cells over-expressing
either GFP or Noc were transfected with a Pparg2 expression
vector and treated with cyclohexamide to inhibit protein synthesis.
Western blot analysis for PPAR-γ2 revealed that, although PPAR-
γ2 levels before cyclohexamide treatment were increased in cells
overexpressing Noc, Noc did not influence the PPAR-γ2 degra-
dation rate (Fig. 2C).
Next, we investigated whether the physical association between
NOC and PPAR-γ2 was part of the deadenylation process. For
this purpose, we used a mutant of NOC (E193A-Noc) that lacked
deadenylase activity. Coimmunoprecipitation analysis revealed
that E193A-Noc bound to PPAR-γ2 in a manner identical to the
WT Noc (Fig. 2A). U-33/γ2 cells expressing E193A-Noc also
showed a significant increase in PPAR-γ2 transcriptional activa-
tion by rosiglitazone (Fig. 2B). To test whether NOC functions as
a transcriptional coactivator for PPAR-γ2, we analyzed the in-
tracellular localization of WT NOC and E193A-NOC. Immuno-
fluorescence and Western blotting analyses confirmed that NOC
was present exclusively in the cytoplasm even in the presence of
PPAR-γ2 activation (Fig. 2 D and E), thereby ruling out the
possibility that NOC acts as a transcriptional coactivator of PPAR-
γ. Taken together, these data demonstrate that NOC binds to
PPAR-γ2 and activates PPAR-γ2 transcriptional activity in
a deadenylase-independent manner.
NOC Stimulates PPAR-γ Nuclear Translocation. To clarify the role of
NOC in PPAR-γ2 activation, we performed immunofluorescence
and found that NOC exhibited perinuclear localization (Fig. 4A).
This finding led us to hypothesize that NOC assisted PPAR-γ2
translocation into the nucleus in part by retaining it at the nu-
clear membrane. To answer this question, we examined in-
tracellular localization of PPAR-γ2 using HEK293 cells
transfected with Pparg2 and Noc. In HEK293 cells PPAR-γ2
mainly resided in the cytoplasm. However, with overexpression
of Noc, PPAR-γ2 translocated into the nucleus even in the ab-
sence of a PPAR-γ2 agonist (Fig. 4 B and C). We also analyzed
the nuclear translocation of PPAR-γ1, and found the same effect
of NOC on PPAR-γ1 nuclear translocation (Fig S4B). Consistent
with these data, the percentage of cells exhibiting nuclear PPAR-
γ expression was reduced in Noc−/− MEFs compared with WT
cells (Fig. 3 B and C). E193A-Noc, the mutated NOC without
deadenylase activity, also facilitated PPAR-γ2 nuclear trans-
location (Fig. 4 B and C), demonstrating that NOC facilitates
PPAR-γ2 nuclear translocation in a deadenylase-independent
manner. In addition, cells expressing N-terminal truncation of
NOC (S64-F429 NOC), which lacks the first 63 amino acids, also
showed enhancement of PPAR-γ2 nuclear transport (Fig S4C).
Finally, to determine the binding site of NOC to PPAR-γ, we
studied the full-length NOC protein and identified a region
(amino acids 341–351) with sequence similarity to an Src ho-
mology 2 domain binding motif. We then generated a short
peptide that corresponded to amino acids 341 to 351 in NOC
and fused it to a TAT protein (20) in its N terminus (NOC-
peptide) to test whether this sequence could prevent the NOC/
PPAR-γ interaction. Addition of NOC-peptide (1 μM) inhibited
the binding of NOC to PPAR-γ2 (Fig. 5A) and significantly
blocked NOC-stimulated endogenous PPAR-γ nuclear trans-
location in 3T3-L1 cells expressing WT-NOC (Fig. 5 B and C). In
addition, NOC-peptide inhibited endogenous PPAR-γ tran-
scriptional activity in 3T3-L1 cells (Fig. 5D).
Next, we investigated whether nuclear translocation of PPAR-γ
by NOC is affected by ligand activation with rosiglitazone and if
rosiglitazone could antagonize the effect of NOC-peptide. Rosi-
Fig. 3. Lack of Noc in MEFs decreases PPAR-γ transcriptional activation by rosiglitazone and PPAR-γ nuclear expression. (A) Mouse MEFs from WT or Noc−/−
mice were transfected with Pparg2 expression vector and PPRE containing luciferase vector. Twenty-four hours after transfection, cells were treated with
1 μM rosiglitazone for 24 h and reporter assay was performed (n = 4–5). (B and C) Immunofluorescence using conforcal microscopy was performed to detect
PPAR-γ expression in WT or Noc−/− MEFs (B) and the percentage of cells exhibiting PPAR-γ nuclear expression was quantitated by immunofluorescence. At
lease 20 cell were counted for quantification (n = 4) (C). Figures shown are the representative of at least three independent experiments. Values are expressed
as the mean ± SEM. *, P < 0.01; **, P < 0.05.
Fig. 4. NOC shows perinuclear localization, and enhances nuclear transport
of PPAR-γ2 in a deadenylase-independent manner. (A) HEK293 cells were
transfected with WT-Noc-Flag expression vector. Noc expression was visual-
ized by immunofluoresence using anti-Flag antibody. DOPE-rhodamine was
used to detect nuclear membrane, and TOPRO3 was used for nuclear
staining. (B and C) HEK293 cells were tranfected with either WT-Noc-Flag or
E193A-Noc-Flag, or a Pparg2 expression vector. Immunofluorescence using
conforcal microscopy was performed to detect PPAR-γ expression (B). Cell
fractionation was performed, and Western blot analysis for PPAR-γ was
carried out. β-actin and Histone-H3 were examined as a positive control for
cytosol and nuclear protein, respectively. The cytosolic fraction from HEK293
cells was used as a positive control for β-actin and a negative control for
Histone-H3 (Left lane in nuclear fraction) (C). Figures shown represent at
least three independent experiments.
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glitazone induced nuclear translocation of PPAR-γ in 3T3-L1
cells expressing GFP (3T3-L1-GFP cells) treated with control
peptide, and treatment with rosiglitazone in 3T3-L1 cells
expressing Noc (3T3-L1-Noc cells) further increased nuclear
translocation of PPAR-γ compared with 3T3-L1-Noc cells, al-
though this did not reach statistical significance (Fig. 5C). In
addition, rosiglitazone partially but significantly blocked the in-
hibitory effect of NOC-peptide on PPAR-γ nuclear translocation.
These lines of evidence suggest that the effect of NOC on PPAR-γ
nuclear translocation is in part mediated by the mechanism in-
dependent of rosiglitazone-induced PPAR-γ nuclear translocation
(Fig. 5C). In sum, NOCmediates nuclear activation of PPAR-γ by
facilitating nuclear transport through binding to the region cor-
responding to amino acid 341 to 351 in the NOC protein.
Body Composition Phenotype of Noc−/− Mice. Previously, we repor-
ted that Noc−/− mice were protected from high-fat diet (HFD)-
induced obesity (19). Generally, Pparg exhibits a circadian
rhythm in liver that is amplified by a HFD (4, 19). However,
Pparg circadian gene expression was absent on a HFD in Noc−/−
mice, suggesting Pparg function could be altered in Noc−/− mice
(19). Thus, we further characterized the adipogenic and skeletal
phenotype of Noc−/− mice to clarify the in vivo consequence of
the lack of Noc. We found that total body weight did not differ
from controls across several time points (Fig. 6A), although
percent body fat was less than controls at 4 wk of age (Fig. 6B).
At 16 wk, Noc−/− mice accumulated more ovarian fat accom-
panied by hypertrophic adipocytes (Fig. 6 C–F). In addition,
Noc−/− mice developed moderate glucose intolerance (Fig. 6G).
In the bone marrow of Noc−/− mice there were fewer adipocytes
compared with controls (Fig S5). The size of brown adipose tissue
(BAT) was not different among the three genotypes of Noc, but
BAT from Noc−/− mice showed an increase in accumulation of
lipid droplets compared with Noc+/+ or Noc+/− mice (Fig S6 A
and B). There was no difference in brown adipogenesis of the
stromal vascular fraction from BAT among the three genotypes
(Fig S6C). Furthermore, BAT-related gene expression was not
different between Noc+/+ and Noc+/− brown adipocytes (Fig
S6D), but expression of Pparg2, aP2, and LRP130 (leucine-rich
PPR motif-containing protein; LRPPRC), which is downstream of
PGC-1α and modulates brown adipocyte function (21), were sig-
nificantly decreased in Noc−/− brown adipocytes (Fig. 6H). Basal
expression of UCP-1 (uncoupling protein 1) and PGC1α did not
differ by genotype (Fig. 6H and Fig S6D), but induction of UCP-1
and PGC1α by forskolin was significantly impaired in the Noc−/−
cells vs. control cells (Fig. 6I). In sum, Noc−/− mice have impaired
ex vivo BAT function, which would be consistent with the lower
basal body temperature reported previously (19).
Fig. 5. Amino acid 341–351 in the NOC protein is responsible for the
binding between NOC and PPAR-γ2. (A) HEK293 cells were tranfected with
a Pparg2 or WT-Noc-Flag expression vector in the presence of 5 μg/mL NOC-
peptide or control peptide, and immunoprecipitation with Flag was fol-
lowed by Western blot analysis for PPAR-γ (n = 4). (B) 3T3-L1 cells over-
expressing GFP or WT-Noc-Flag were incubated with NOC-peptide or control
peptide, and the expression of PPAR-γ and Noc was visualized by immuno-
fluorescence. (C) 3T3-L1 cells overexpressing GFP or WT-Noc-Flag were in-
cubated with NOC-peptide or control peptide in the presence of DMSO or
1 μM of rosiglitazone (ROZ) and the percentage of cells exhibiting PPAR-γ
nuclear translocation was quantitated by immunofluorescence. At lease 20
cell were counted for quantification (n = 5). (D) 3T3-L1 cells were transfected
with PPRE-Luc construct in the presence of 5 μg/mL NOC-peptide or control
peptide, and luciferase assay was performed at day 2 (n = 4). Figures shown
represent at least four independent experiments. Values are expressed as
the mean ± SEM. *, P < 0.05; a, P < 0.0001; b, P < 0.001; c, P < 0.01; d, P < 0.05.
Fig. 6. Body composition and fat characteristics of Noc−/− mice. (A and B)
Body weight (A) and percent body fat (B) was measured in Noc+/+ (n = 13–16)
and Noc−/− (n = 10) mice at the ages indicated. (C and D) The gross ap-
pearance of the ovarian fat pad (arrow in C) and ovarian fat pad weight (D)
was examined in 16-wk-old Noc+/+ (n = 8) and Noc−/− (n = 5) mice. (E and F)
The ovarian fat pad from 6- and 16-wk-old mice was examined histologically
by H&E staining (E), and the number of adipocytes per field was determined
(n = 4) (F). (G) Glucose tolerance was determined at 8 (n = 9–13) and 16 wk of
age (n = 7). (H and I) Primary brown preadipocytes from 10-d-old mice were
differentiated to brown adipocytes and the expression of brown adipocyte-
related genes was examined by real-time PCR (n = 4–5) (H). Primary brown
adipocytes were treated with forskolin (10 μM) for 4 h and expression of
PGC1α and UCP-1 was analyzed by real-time PCR (n = 3) (I). (J) Trabecular BV/
TV in distal femur was measured by microCT (Left, n = 25–26), and cortical
thickness at the midshaft of femur was assessed by peripheral quantitative
CT (Right, n = 21) at 16 wk of age. Values are expressed as the mean ± SEM.
*, P < 0.05; **, P < 0.01.








In respect to skeletal composition,Noc−/− mice exhibited higher
areal whole-body and femoral bone mineral density (aBMD) than
controls (Table S1). Femoral areal bone mineral content (aBMC)
was significantly higher in Noc−/− mice vs. controls (Table S1).
This phenotype was primarily because of a larger cortical com-
partment and longer femorae (Fig. 6J and Tables S2 and S3).
Bone volume fraction in the femur as measured by microCT in
16-wk Noc−/− mice was significantly greater than controls princi-
pally becuase of enhanced trabecular thickness (Fig. 6J and Table
S3). Thus, NOC plays an important role in regulating body com-
position by affecting both hard and soft tissues.
Discussion
The process of adipogenesis includes the differentiation of
BMSCs under the influence of adipocyte-specific transcription
factors (22, 23). PPAR-γ activation is essential for this process
and here we show that NOC enhances PPAR-γ nuclear trans-
location. Of importance is that although NOC facilitates PPAR-γ
nuclear translocation, a PPAR-γ ligand (endogenous or exoge-
nous) is required to activate PPAR-γ transcriptional activity.
NOC is a member of a family of proteins that include tran-
scription factors, deadenylases and phosphatases (24). It shares
significant sequence similarity to the multifunctional yeast pro-
tein Ccr4p, a transcription factor that is involved in regulation of
global gene expression in response to nutrient status, in addition
to its role as a deadenylase (12, 24, 25). Our initial findings raised
the possibility that NOC was functioning at the level of tran-
scription to regulate cell differentiation. However, mammalian
NOC lacks the N-terminus activating domain, which Ccr4p
possesses (12). In addition, NOC was not detected in the nucleus
even with PPAR-γ2 activation, ruling out the possibility that it
was a coactivator of PPAR-γ.
Previously PPAR-γ was considered solely in the context of its
role as a nuclear receptor and transcription factor, even though
cytosolic localization of PPAR-γ has been reported frequently
(26–29). However, a nuclear localization signal has never been
identified for PPAR-γ, although there is evidence that it is
exported from the nucleus in a MEK-dependent manner (30).
Thus, the precise mechanism underlying PPAR-γ nuclear
translocation remains elusive. Nuclear transport must involve
either molecular size-based diffusion or a transport factor acting
as a chaperone (31, 32). Our findings raise the intriguing possi-
bility that NOC is involved in the translocation of PPAR-γ, al-
though its absence in the nucleus implies that NOC must
function in collaboration with other transport mechanisms to
complete the nuclear translocation of PPAR-γ.
In support of that tenet, we found that Noc is induced tran-
siently in early adipogenesis, and then is robustly up-regulated
during the latter phases of differentiation in 3T3-L1 cells. The
early up-regulation of Noc can be induced by FCS or insulin (15)
and may be a critical step in activating PPAR-γ. Indeed, we
found that silencing Noc resulted in impaired induction of Pparg
transcripts during early adipogenesis in 3T3-L1 cells. Previously,
we reported that in U-33 mesenchymal stromal cells transfected
with a Pparg2 expression construct and treated with rosiglita-
zone, Noc expression was enhanced nearly 30-fold, implying that
Noc was a down-stream target of Pparg (16). In addition, a Pparg
“gain-of-function” 6T congenic mouse, which exhibits low bone
mass and high marrow adiposity, showed increased Noc expres-
sion in fat, liver, and bone marrow (17, 33). Thus, the robust up-
regulation of Noc expression in late adipogenesis may be
explained in part by increased Pparg expression. In sum, Noc and
Pparg may activate each other during adipogenesis, although we
cannot rule out the possibility that Noc may also function to
deadenylate one of the 3′UTR forms of Pparg, thereby acting as
negative feedback on nuclear receptor activation.
Further evidence that NOC is important in PPAR-γ regulation
comes from our in vivo studies of Noc−/− mice. These mice have
high bone mass and reduced marrow adiposity, a phenotype
remarkably similar to that reported in Pparg+/− mice (6).
Moreover, the absence of Pparg circadian rhythmicity in the
Noc−/− mice, even on a HFD, suggests that NOC modulates
PPAR-γ activity in a forward direction.
It is well established that PPAR-γ is an important regulator of
mesenchymal stem-cell fate, and its activation favors adipogenesis
over osteoblastogenesis partly by suppressing osteogenic signaling
pathways, such as Wnt, TGFβ/BMP, IGF-I, and transcription fac-
tors, including Runx2 and OSX (osterix) (16, 34–36). Because
Pparg expression is lower and Runx2 expression is higher in Noc−/−
COBs compared with control cells, alterations in cell specification
of BMSCs may be responsible for the skeletal phenotype ofNoc−/−
mice. Similarly, mice with a conditional deletion of circadian genes
in osteoblasts, such as period and cryptochrome, also exhibit a high
bone-mass phenotype (11). Moreover, type I collagen and osteo-
calcin exhibit significant periodicity during a 24-h cycle, suggesting
that bone remodeling is under the control of the circadian clock
(37). Because Noc may also be regulated by other clock genes (38,
39) that are important in bone turnover, it is conceivable that Noc
modulates skeletal acquisition by functioning as a downstream
modulator of osteoblast differentiation.
Adjusting cell behavior to energy availability is a central
function of cell physiology (1). Recently, Lamia et al. reported
that AMPK, a peripheral sensor of nutrient availability, phos-
phorylates cryptochrome 1, thereby promoting its ubiquitination
and subsequent degradation (40). Previously, we have shown that
Noc is rapidly induced in NIH 3T3 cells by FCS (15). In this study,
we found that Noc was up-regulated by FCS and insulin in 3T3-L1
preadipocytes (Fig S7). Noc was also up-regulated by FCS in
BMSCs, but the induction was not as great as that in 3T3-L1 cells
(Fig S7). Insulin did not have any effect on Noc induction in
BMSCs. These findings suggest that Noc expression is regulated by
external stimuli, although the effect on Noc induction is likely to
be cell-specific. The possibility that NOC regulates PPAR-γ nu-
clear transport provides a unique mechanism whereby fine tuning
of adipogenesis can occur in response to entrainment from nu-
trient excess. The evolution of Noc in the mammalian organism as
a nuclear activator for PPAR-γ raises a series of provocative
questions about the role energy sufficiency plays in skeletal and
adipogenic homeostasis and how environmentally induced alter-
ations could ultimately affect body composition.
Methods
Mice. Generation of Ccrn4ltmlBjc, which we refer to nocturnin knockout mice
(Noc−/− mice) has been described previously (19). The original mice were
backcrossed onto C57BL/6J background for at least seven generations. All
experimental studies were performed using female mice. All of the animal
studies were reviewed and approved by the Institutional Animal Care and
Use Committee of Maine Medical Center Research Institute.
Cell Culture. See SI Methods for details.
Constructs. The pCMV-WT-Noc-Flag, and pCMV-E193A-Noc-Flag vector, which
harbors a point mutation in the Mg2+ binding motif leading to loss of
deadenylase activity, have been previously described (15). Details for other
constructs are described in SI Methods.
Body Composition and Skeletal Phenotyping of Noc−/− Mice. Whole-body
aBMD and aBMC, femoral aBMD and aBMC, and body composition were
analyzed using dual-energy x-ray absorptiometry. Peripheral quantitative CT
was used to analyze femur length and cortical thickness. Microarchitecture of
distal trabecular bone andmidshaft cortical bone of femur were evaluated by
MicroCT. See SI Methods for details.
Analysis for the Role of NOC in Adipogenesis and Osteoblastogenesis. Noc was
overexpressed using retrovirus in 3T3-L1 cells and MC3T3-E1 cells to evaluate
the role of NOC in adipogenesis and osteoblastogenesis. Noc expression was
suppressed using small interfering RNA or short-hairpin RNA in 3T3-L1 cells and
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MC3T3-E1 cells. The expression of marker genes and specific staining were used
to evaluate adipogenesis and osteoblastogenesis as described in SI Methods.
Intracellular Localization of NOC and PPAR-γ2. Intracellular localization of NOC
was analyzed by immunofluorescence andWestern blot analyses as described
in SI Methods. A lipophilic tracer [either DiIC18(5) (DiD) or DOPE-rhodamine]
was used to visualize nuclear membrane. For nuclear staining, cells were
stained with either TOPRO3 or SYTOX (Invitrogen).
Analysis of Interaction Between NOC and PPAR-γ2. To analyze the physical
interaction between NOC and PPAR-γ2, HEK293 cells were transfected with
Pparg2 expression vector and either WT-Noc-Flag or E193A-Noc-Flag ex-
pression vector, and immunoprecipitated with anti-Flag antibody. Then,
Western blot analysis for PPAR-γ was performed as described in SI Methods.
Reporter assay using PPRE-Luc vector was performed in HEK293 cells to
analyze the role of NOC in Pparg transcriptional activity as described in
SI Methods.
Statistical Analysis. All data are expressed as the mean ± SEM. Results were
analyzed for statistically significant differences using Student’s t test or
ANOVA followed by Bonferroni multiple comparison post hoc test. The
glucose tolerance test was analyzed using repeat measures ANOVA. Statis-
tical significance was set at P < 0.05.
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